Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Open accessAbstract
Monoclonal antibodies have revolutionized cancer therapy. However, delivery to tumor cells in vivo is hampered by the large size (150 kDa) of conventional antibodies. The minimal target recognition module of a conventional antibody is composed of two non-covalently associated variable domains (VH and VL). The proper orientation of these domains is mediated by their hydrophobic interface and is stabilized by their linkage to disulfide-linked constant domains (CH1 and CL). VH and VL domains can be fused via a genetic linker into a single chain variable fragment (scFv). scFv modules in turn can be fused to one another, e.g. to generate a bispecific T cell engager (BiTE), or they can be fused in various orientations to antibody hinge and Fc domains to generate bi- and multispecific antibodies. However, the inherent hydrophobic interaction of VH and VL domains limits the stability and solubility of engineered antibodies, often causing aggregation and/or mispairing of V-domains. Nanobodies (15 kDa) and nanobody-based human heavy chain antibodies (75 kDa) can overcome these limitations. Camelids naturally produce antibodies composed only of heavy chains in which the target recognition module is composed of a single variable domain (VHH or nanobody). Advantageous features of nanobodies include their small size, high solubility, high stability, and excellent tissue penetration in vivo. Nanobodies can readily be linked genetically to Fc-domains, other nanobodies, peptide tags, or toxins and can be conjugated chemically at a specific site to drugs, radionuclides, photosensitizers, and nanoparticles. These properties make them particularly suited for specific and efficient targeting of tumors in vivo. Chimeric nanobody-heavy chain antibodies combine advantageous features of nanobodies and human Fc domains in about half the size of a conventional antibody. In this review, we discuss recent developments and perspectives for applications of nanobodies and nanobody-based human heavy chain antibodies as anti-tumor therapeutics.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The accumulated methodology of computational antibody protocols could potentially be applied to novel antibody formats with intrinsically better biophysical properties, such as nanobodies.
“The accumulated methodology of computational antibody protocols could potentially be applied to novel antibody formats with intrinsically better biophysical properties, such as nanobodies [27].”
From Computational approaches to therapeutic antibody design: established methods and emerging trends (2020) · cites this paper as [27]
Single domain antibodies have attracted attention because of their smaller size and better biophysical properties with respect to antibodies (higher stability and lower suspected immunogenicity).
“Single domain antibodies have attracted attention because of their smaller size and better biophysical properties with respect to antibodies (higher stability and lower suspected immunogenicity) [27].”
From Computational approaches to therapeutic antibody design: established methods and emerging trends (2020) · cites this paper as [27]
Nanobodies are naturally occurring H chain only antibodies in camelids and sharks.
“One of the most promising is the H chain only antibody, or nanobody that are naturally occurring in camelids (llamas, alpacas and camels) [27] and sharks [228, 229] (reviewed by Muyldermans [230] and Bannas et al. [27]).”
From Computational approaches to therapeutic antibody design: established methods and emerging trends (2020) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241 · see citing works
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,196 · see citing works
Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries
Jostock, T., Vanhove, M., Brepoels, E., van Gool, R., Daukandt, M., Wehnert, A., van Hegelsom, R., Dransfield, D., Sexton, D., Devlin, M., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.03.014 · Cited by 2,562 · see citing works
Nanobodies: natural single-domain antibodies
Muyldermans, S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-063011-092449 · Cited by 2,304 · see citing works
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3236 · Cited by 2,167 · see citing works
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,156 · see citing works
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. P. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562 · see citing works
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362 · see citing works
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324 · see citing works
The therapeutic monoclonal antibody market
Ecker, D. M., Jones, S. D., & Levine, H. L. (2014) · mAbs · doi:10.4161/19420862.2015.989042 · Cited by 1,292 · see citing works
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 933 · see citing works
‘Knobs-into-holes’ engineering of antibody C H 3 domains for heavy chain heterodimerization
Ridgway, J. B., Presta, L. G., & Carter, P. M. (1996) · Protein Engineering Design and Selection · doi:10.1093/protein/9.7.617 · Cited by 816 · see citing works
The immunogenicity of humanized and fully human antibodies
Harding, F., Stickler, M. M., Razo, J., & DuBridge, R. B. (2010) · mAbs · doi:10.4161/mabs.2.3.11641 · Cited by 743 · see citing works
A minimal peptide substrate in biotin holoenzyme synthetase‐catalyzed biotinylation
Beckett, D., Kovaleva, E. G., & Schatz, P. J. (1999) · Protein Science · doi:10.1110/ps.8.4.921 · Cited by 727 · see citing works
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
Peyvandi, F., Scully, M., Hovinga, J. A. K., Cataland, S. R., Knöbl, P., Wu, H. M., Artoni, A., Westwood, J., Taleghani, M. M., Jilma, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505533 · Cited by 667 · see citing works
Stability engineering of antibody single-chain Fv fragments
Wörn, A., & Plückthun, A. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4265 · Cited by 616 · see citing works
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607 · see citing works
Kontermann, R. E., & Brinkmann, U. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.008 · Cited by 585 · see citing works
Single domain camel antibodies: current status
Muyldermans, S. (2001) · Reviews in Molecular Biotechnology · doi:10.1016/s1389-0352(01)00021-6 · Cited by 553 · see citing works
Therapeutic antibodies for human diseases at the dawn of the twenty-first century
Brekke, O. H., & Sandlie, I. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd984 · Cited by 552 · see citing works
Sortagging: a versatile method for protein labeling
Popp, M. W., Antos, J. M., Grotenbreg, G. M., Spooner, E., & Ploegh, H. L. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.31 · Cited by 535 · see citing works
Single domain antibodies: promising experimental and therapeutic tools in infection and immunity
Wesolowski, J., Alzogaray, V., Reyelt, J., Unger, M., Juárez‐Moreno, K., Urrutia, M., Cauerhff, A., Danquah, W., Rissiek, B., Scheuplein, F., et al. (2009) · Medical Microbiology and Immunology · doi:10.1007/s00430-009-0116-7 · Cited by 516 · see citing works
Muyldermans, S., Atarhouch, T., Saldanha, J. W., Barbosa, J. A. R. G., & HAMERS, R. (1994) · Protein Engineering Design and Selection · doi:10.1093/protein/7.9.1129 · Cited by 495 · see citing works
Nanobodies as therapeutics: big opportunities for small antibodies
Steeland, S., Vandenbroucke, R. E., & Libert, C. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.003 · Cited by 462 · see citing works
Engineering Natural Killer Cells for Cancer Immunotherapy
Rezvani, K., Rouce, R. H., Liu, E., & Shpall, E. J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.012 · Cited by 454 · see citing works
Nanobody-based products as research and diagnostic tools
Meyer, T. D., Muyldermans, S., & Depicker, A. G. (2014) · Trends in biotechnology · doi:10.1016/j.tibtech.2014.03.001 · Cited by 450 · see citing works
Ligand-targeted liposomal anticancer drugs
Sapra, P., & Allen, T. M. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00032-8 · Cited by 438 · see citing works
Site-Specific Biotinylation of Purified Proteins Using BirA
Fairhead, M., & Howarth, M. R. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-2272-7_12 · Cited by 405 · see citing works
Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes
Krishna, M., & Nadler, S. G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00021 · Cited by 389 · see citing works
Efficient Cancer Therapy with a Nanobody-Based Conjugate
Cortez‐Retamozo, V., Backmann, N., Senter, P. D., Wernery, U., BAETSELIER, P. D., Muyldermans, S., & Revets, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3935 · Cited by 383 · see citing works
Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies
Roovers, R. C., Laeremans, T., Huang, L., Taeye, S. D., Verkleij, A. J., Revets, H., de Haard, H., & Henegouwen, P. M. P. V. B. E. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0180-4 · Cited by 348 · see citing works
Phage display-derived human antibodies in clinical development and therapy
Frenzel, A., Schirrmann, T., & Hust, M. (2016) · mAbs · doi:10.1080/19420862.2016.1212149 · Cited by 346 · see citing works
Immunotoxins for targeted cancer therapy
Kreitman, R. J. (2006) · The AAPS Journal · doi:10.1208/aapsj080363 · Cited by 308 · see citing works
Tijink, B. M., Laeremans, T., Budde, M., van Walsum, M., Dreier, T., de Haard, H., Leemans, C. R., & van Dongen, G. A. M. S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2384 · Cited by 306 · see citing works
Coppieters, K. T., Dreier, T., Silence, K., de Haard, H., Lauwereys, M., Casteels, P., Beirnaert, E., Jonckheere, H., de Wiele, C. V., Staelens, L., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21827 · Cited by 303 · see citing works
Conrath, K., Lauwereys, M., Wyns, L., & Muyldermans, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007734200 · Cited by 301 · see citing works
AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges
Gardner, M. R., Kattenhorn, L. M., Kondur, H. R., von Schaewen, M., Dorfman, T., Chiang, J. J., Haworth, K. G., Decker, J. M., Alpert, M. D., Bailey, C. C., et al. (2015) · Nature · doi:10.1038/nature14264 · Cited by 299 · see citing works
Movahedi, K., Schoonooghe, S., Laoui, D., Houbracken, I., Waelput, W., Breckpot, K., Bouwens, L., Lahoutte, T., BAETSELIER, P. D., Raes, G., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2994 · Cited by 292 · see citing works
Nanobody: The “Magic Bullet” for Molecular Imaging?
Chakravarty, R., Goel, S., & Cai, W. (2014) · Theranostics · doi:10.7150/thno.8006 · Cited by 288 · see citing works
Seimetz, D., Lindhofer, H., & Bokemeyer, C. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.03.001 · Cited by 284 · see citing works
A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth
Roovers, R. C., Vosjan, M. J. W. D., Laeremans, T., el Khoulati, R., de Bruin, R. C. G., Ferguson, K. M., Verkleij, A. J., van Dongen, G. A. M. S., & Henegouwen, P. M. P. V. B. E. (2011) · International Journal of Cancer · doi:10.1002/ijc.26145 · Cited by 284 · see citing works
Current progress in innovative engineered antibodies
Strohl, W. R. (2017) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 282 · see citing works
Antibody constructs in cancer therapy
Beckman, R. A., Weiner, L. M., & Davis, H. M. (2006) · Cancer · doi:10.1002/cncr.22402 · Cited by 280 · see citing works
Nanobody-Based Cancer Therapy of Solid Tumors
Kijanka, M. M., Dorresteijn, B., Oliveira, S., & Henegouwen, P. M. P. V. B. E. (2015) · Nanomedicine · doi:10.2217/nnm.14.178 · Cited by 265 · see citing works
Efficient tumor targeting by single‐domain antibody fragments of camels
Cortez‐Retamozo, V., Lauwereys, M., Gh., G. H., Gobert, M., Conrath, K., Muyldermans, S., BAETSELIER, P. D., & Revets, H. (2002) · International Journal of Cancer · doi:10.1002/ijc.10212 · Cited by 260 · see citing works
Nanobodies as novel agents for cancer therapy
Revets, H., BAETSELIER, P. D., & Muyldermans, S. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.1.111 · Cited by 254 · see citing works
Structural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH Domains
Schmitz, K. R., Bagchi, A., Roovers, R. C., Henegouwen, P. M. P. V. B. E., & Ferguson, K. M. (2013) · Structure · doi:10.1016/j.str.2013.05.008 · Cited by 251 · see citing works
Jähnichen, S., Blanchetot, C., Maussang, D., González-Pajuelo, M., Chow, K. Y. C., Bosch, L., Vrieze, S. D., Serruys, B., Ulrichts, H., Vandevelde, W., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012865107 · Cited by 251 · see citing works
Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells
Rashidian, M., Ingram, J. R., Dougan, M. L., Dongre, A., Whang, K. A., Gall, C. M. L., Cragnolini, J. J., Bierie, B., Gostissa, M., Gorman, J. R., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20161950 · Cited by 247 · see citing works
A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme
Dumoulin, M., Last, A. M., Desmyter, A., Decanniere, K., Canet, D., Larsson, G., Spencer, A. G., Archer, D. B., Sasse, J., Muyldermans, S., et al. (2003) · Nature · doi:10.1038/nature01870 · Cited by 245 · see citing works
Pleiner, T., Bates, M., Trakhanov, S. D., Lee, C., Schliep, J. E., Chug, H., Böhning, M., Stark, H., Urlaub, H., & Görlich, D. (2015) · eLife · doi:10.7554/elife.11349 · Cited by 242 · see citing works
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
Zhang, F., Wei, H., Wang, X., Bai, Y., Wang, P., Wu, J., Jiang, X., Wang, Y., Cai, H., Xu, T., et al. (2017) · Cell Discovery · doi:10.1038/celldisc.2017.4 · Cited by 229 · see citing works
Nanobodies as Versatile Tools to Understand, Diagnose, Visualize and Treat Cancer
Audenhove, I. V., & Gettemans, J. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.028 · Cited by 228 · see citing works
Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody
D’Huyvetter, M., Vincke, C., Xavier, C., Aerts, A., Impens, N. R. E. N., Baatout, S., Raeve, H. D., Muyldermans, S., Caveliers, V., Devoogdt, N., et al. (2014) · Theranostics · doi:10.7150/thno.8156 · Cited by 226 · see citing works
Gainkam, L. O. T., Huang, L., Caveliers, V., Keyaerts, M., Hernot, S., Vaneycken, I., Vanhove, C., Revets, H., BAETSELIER, P. D., & Lahoutte, T. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.048538 · Cited by 222 · see citing works
Noninvasive imaging of immune responses
Rashidian, M., Keliher, E. J., Bilate, A. M. B., Duarte, J. N., Wojtkiewicz, G. R., Jacobsen, J. T., Cragnolini, J., Swee, L. K., Victora, G. D., Weissleder, R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502609112 · Cited by 218 · see citing works
Lindhofer, H., Mocikat, R., Steipe, B., & Thierfelder, S. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.1.219 · Cited by 213 · cited 1× · see citing works
“, rat IgG2a and rat lambda on the one side and mouse IgG2b and mouse kappa on the other side, reduces mispairing of the VL and VH domains (50).”
BackgroundFormation of a bispecific antibody by the use of leucine zippers
Kostelny, S. A., Cole, M. S., & Tso, J. Y. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.5.1547 · Cited by 211 · see citing works
Targeting tumors with nanobodies for cancer imaging and therapy
Oliveira, S., Heukers, R., Sornkom, J., Kok, R. J., & Henegouwen, P. M. P. V. B. E. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.08.298 · Cited by 206 · see citing works
Oliveira, S., van Dongen, G. A. M. S., van Walsum, M., Roovers, R. C., Stam, J. C., Mali, W. P. T. M., van Diest, P. J., & Henegouwen, P. M. P. V. B. E. (2012) · Molecular Imaging · doi:10.2310/7290.2011.00025 · Cited by 194 · see citing works
SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression
Huang, L., Gainkam, L. O. T., Caveliers, V., Vanhove, C., Keyaerts, M., BAETSELIER, P. D., Bossuyt, A. M., Revets, H., & Lahoutte, T. (2008) · Molecular Imaging and Biology · doi:10.1007/s11307-008-0133-8 · Cited by 192 · see citing works
Beghein, E., & Gettemans, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00771 · Cited by 190 · see citing works
Kuus-Reichel, K., Grauer, L. S., Karavodin, L. M., Knott, C., Krusemeier, M., & Kay, N. E. (1994) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.1.4.365-372.1994 · Cited by 185 · see citing works
Massa, S., Xavier, C., Vos, J. D., Caveliers, V., Lahoutte, T., Muyldermans, S., & Devoogdt, N. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500111t · Cited by 184 · see citing works
Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation
Danquah, W., Meyer‐Schwesinger, C., Rissiek, B., Pinto, C., Prat, A. S., Amadi, M., Iacenda, D., Knop, J., Hammel, A., Bergmann, P., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8463 · Cited by 182 · see citing works
Dekempeneer, Y., Keyaerts, M., Krasniqi, A., Puttemans, J., Muyldermans, S., Lahoutte, T., D’Huyvetter, M., & Devoogdt, N. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1185412 · Cited by 171 · see citing works
van Driel, P. B. A. A., Boonstra, M. C., Slooter, M. D., Heukers, R., Stammes, M. A., Snoeks, T. J. A., de Bruijn, H. S., van Diest, P. J., Vahrmeijer, A. L., Henegouwen, P. M. P. V. B. E., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.03.014 · Cited by 167 · see citing works
Papadopoulos, K. P., ISAACS, R. E., Bilic, S., Kentsch, K., Huet, H. A., Hofmann, M., Rasco, D. W., Kundamal, N., Tang, Z., Cooksey, J., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2712-0 · Cited by 162 · see citing works
Blykers, A., Schoonooghe, S., Xavier, C., D’hoe, K., Laoui, D., D’Huyvetter, M., Vaneycken, I., Cleeren, F., Bormans, G. M., Heemskerk, J., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.156828 · Cited by 160 · see citing works
Single domain antibodies: comparison of camel VH and camelised human VH domains
Riechmann, L., & Muyldermans, S. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(99)00138-6 · Cited by 156 · see citing works
Downregulation of EGFR by a novel multivalent nanobody-liposome platform
Oliveira, S., Schiffelers, R. M., van der Veeken, J., van der Meel, R., Vongpromek, R., Henegouwen, P. M. P. V. B. E., Storm, G., & Roovers, R. C. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.03.020 · Cited by 149 · see citing works
Maussang, D., Mujić-Delić, A., Descamps, F. J., Stortelers, C., Vanlandschoot, P., van Walsum, M., Vischer, H. F., Roy, M. V., Vosjan, M. J. W. D., González-Pajuelo, M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.498436 · Cited by 148 · see citing works
Gainkam, L. O. T., Caveliers, V., Devoogdt, N., Vanhove, C., Xavier, C., Boerman, O. C., Muyldermans, S., Bossuyt, A. M., & Lahoutte, T. (2010) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.408 · Cited by 148 · see citing works
Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy
Vosjan, M. J. W. D., Vercammen, J., Kolkman, J. A., van Walsum, M., Revets, H., & van Dongen, G. A. M. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0891 · Cited by 146 · see citing works
The development of nanobodies for therapeutic applications.
Bockstaele, F. V., Holz, J.-B., & Revets, H. (2009) · PubMed · Cited by 144 · see citing works
Hmila, I., Abderrazek, R. B., Saerens, D., Benlasfar, Z., Conrath, K., Ayeb, M. E., Muyldermans, S., & Bouhaouala‐Zahar, B. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.04.011 · Cited by 140 · see citing works
Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy
Talelli, M., Oliveira, S., Rijcken, C. J. F., Pieters, E. H. E., Etrych, T., Ulbrich, K., van Nostrum, R., Storm, G., Hennink, W. E., & Lammers, T. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.064 · Cited by 132 · see citing works
Vos, J. D., Devoogdt, N., Lahoutte, T., & Muyldermans, S. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.800478 · Cited by 128 · see citing works
Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer
D’Huyvetter, M., Xavier, C., Caveliers, V., Lahoutte, T., Muyldermans, S., & Devoogdt, N. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.941803 · Cited by 124 · see citing works
Baker, J. H. E., Lindquist, K. E., Huxham, L. A., Kyle, A. H., Sy, J., & Minchinton, A. I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4465 · Cited by 124 · see citing works
Koch‐Nolte, F., Reyelt, J., Schößow, B., Schwarz, N., Scheuplein, F., Rothenburg, S., Haag, F., Alzogaray, V., Cauerhff, A., & Goldbaum, F. A. (2007) · The FASEB Journal · doi:10.1096/fj.07-8661com · Cited by 119 · see citing works
van Schie, K. A., Wolbink, G., & Rispens, T. (2015) · mAbs · doi:10.1080/19420862.2015.1048411 · Cited by 117 · see citing works
Altıntaş, I., Heukers, R., van der Meel, R., Lacombe, M., Amidi, M., Henegouwen, P. M. P. V. B. E., Hennink, W. E., Schiffelers, R. M., & Kok, R. J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.11.007 · Cited by 116 · see citing works
Talelli, M., Rijcken, C. J. F., Oliveira, S., van der Meel, R., Henegouwen, P. M. P. V. B. E., Lammers, T., van Nostrum, C. F., Storm, G., & Hennink, W. E. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.01.015 · Cited by 113 · see citing works
Albert, S., Arndt, C., Feldmann, A., Bergmann, R., Bachmann, D., Koristka, S., Ludwig, F., Ziller-Walter, P., Kegler, A., Gärtner, S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1287246 · Cited by 112 · see citing works
Introduction to Heavy Chain Antibodies and Derived Nanobodies
Vincke, C., & Muyldermans, S. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-968-6_2 · Cited by 110 · see citing works
Immunogenicity of therapeutic recombinant immunotoxins
Mazor, R., Onda, M., & Pastan, I. H. (2016) · Immunological Reviews · doi:10.1111/imr.12390 · Cited by 110 · see citing works
Huet, H. A., Growney, J. D., Johnson, J. A., Li, J., Bilic, S., Ostrom, L., Zafari, M. R., Kowal, C., Yang, G., Royo, A., et al. (2014) · mAbs · doi:10.4161/19420862.2014.975099 · Cited by 109 · see citing works
Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds
Liu, H.-Y., Saxena, A., Sidhu, S., & Wu, D.-H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00038 · Cited by 109 · see citing works
Debie, P., Quathem, J. V., Hansen, I., Bala, G., Massa, S., Devoogdt, N., Xavier, C., & Hernot, S. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01053 · Cited by 106 · see citing works
Nardis, C. D., Hendriks, L. J. A., Poirier, E., Arvinte, T., Gros, P., Bakker, A. B. H., & de Kruif, J. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.793497 · Cited by 105 · see citing works
van der Meel, R., Oliveira, S., Altıntaş, I., Haselberg, R., van der Veeken, J., Roovers, R. C., Henegouwen, P. M. P. V. B. E., Storm, G., Hennink, W. E., Schiffelers, R. M., et al. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.027 · Cited by 104 · see citing works
Nanobody–photosensitizer conjugates for targeted photodynamic therapy
Heukers, R., Henegouwen, P. M. P. V. B. E., & Oliveira, S. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.12.007 · Cited by 100 · see citing works
The Human Immune Response to the OKT3 Monoclonal Antibody Is Oligoclonal
Chatenoud, L., Jonker, M., Villemain, F., Goldstein, G., & Bach, J. (1986) · Science · doi:10.1126/science.3086976 · Cited by 98 · see citing works
Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies
Lemaire, M., D’Huyvetter, M., Lahoutte, T., Valckenborgh, E. V., Menu, E., Bruyne, E. D., Kronenberger, P., Wernery, U., Muyldermans, S., Devoogdt, N., et al. (2013) · Leukemia · doi:10.1038/leu.2013.292 · Cited by 98 · see citing works
Novel Antiplatelet Agents: ALX-0081, a Nanobody Directed towards von Willebrand Factor
Bartúnek, J., Barbato, E., Heyndrickx, G. R., Vanderheyden, M., Wijns, W. C., & Holz, J.-B. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9435-y · Cited by 92 · see citing works
Jamnani, F. R., Rahbarizadeh, F., Shokrgozar, M. A., Mahboudi, F., Ahmadvand, D., Sharifzadeh, Z., Parhamifar, L., & Moghimi, S. M. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.09.029 · Cited by 91 · see citing works
Behdani, M., Zeinali, S., Karimipour, M., Khanahmad, H., Schoonooghe, S., Aslemarz, A., Seyed, N., Moazzami, R., Baniahmad, F., Habibi‐Anbouhi, M., et al. (2012) · New Biotechnology · doi:10.1016/j.nbt.2012.09.002 · Cited by 85 · see citing works
Heukers, R., Altıntaş, I., Raghoenath, S., Zan, E. D., Pepermans, R. A., Roovers, R. C., Haselberg, R., Hennink, W. E., Schiffelers, R. M., Kok, R. J., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.001 · Cited by 83 · see citing works
Iqbal, U. H., Trojahn, U., Albaghdadi, H., Zhang, J., O'Connor‐McCourt, M. D., Stanimirovic, D. B., Tomanek, B., Sutherland, G. R., & Abulrob, A. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00742.x · Cited by 81 · see citing works
Sheng, Z., Schramm, C. A., Kong, R., Program, N. C. S., Mullikin, J. C., Mascola, J. R., Kwong, P. D., & Shapiro, L. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00537 · Cited by 78 · see citing works
Immuno-targeting the multifunctional CD38 using nanobody
Li, T., Qi, S., Unger, M., Hou, Y. N., Deng, Q. W., Liu, J., Lam, C. M. C., Wang, X. W., Du, X., Zhang, P., et al. (2016) · Scientific Reports · doi:10.1038/srep27055 · Cited by 75 · see citing works
Unger, M., Eichhoff, A. M., Schumacher, L., Strysio, M., Menzel, S., Schwan, C., Alzogaray, V., Zylberman, V., Séman, M., Brandner, J. M., et al. (2015) · Scientific Reports · doi:10.1038/srep07850 · Cited by 72 · see citing works
Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody
Kazemi‐Lomedasht, F., Behdani, M., Bagheri, K. P., Habibi‐Anbouhi, M., Abolhassani, M., Arezumand, R., Shahbazzadeh, D., & Mirzahoseini, H. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.010 · Cited by 70 · see citing works
Evazalipour, M., D’Huyvetter, M., Tehrani, B. S., Abolhassani, M., Omidfar, K., Abdoli, S., Arezumand, R., Morovvati, H., Lahoutte, T., Muyldermans, S., et al. (2014) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1558 · Cited by 70 · see citing works
Yuan, Y. J., Li, J., Zhu, X., Tang, X., Bao, Y., Sun, X., Huang, Y., Tian, F., Liu, X., & Yang, L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s127575 · Cited by 69 · see citing works
Sadeqzadeh, E., Rahbarizadeh, F., Ahmadvand, D., Rasaee, M. J., Parhamifar, L., & Moghimi, S. M. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.022 · Cited by 66 · see citing works
Jamnani, F. R., Rahbarizadeh, F., Shokrgozar, M. A., Ahmadvand, D., Mahboudi, F., & Sharifzadeh, Z. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.03.004 · Cited by 62 · see citing works
Deng, C., Xiong, J., Gu, X., Chen, X., Wu, S., Wang, Z., Wang, D., Tu, J., & Xie, J. (2017) · Oncotarget · doi:10.18632/oncotarget.16930 · Cited by 58 · see citing works
Nanobody-functionalized PEG-b-PCL polymersomes and their targeting study
Zou, T., Dembele, F., Beugnet, A., Sengmanivong, L., Trépout, S., Marco, S., de Marco, A., & Li, M. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.09.034 · Cited by 57 · see citing works
Antibody gene transfer with adeno‐associated viral vectors as a method for HIV prevention
Brady, J. M., Baltimore, D., & Balazs, A. B. (2017) · Immunological Reviews · doi:10.1111/imr.12478 · Cited by 57 · see citing works
Bannas, P., Lenz, A., Kunick, V., Well, L., Fumey, W., Rissiek, B., Haag, F., Schmid, J., Schütze, K., Eichhoff, A. M., et al. (2015) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1637 · Cited by 55 · see citing works
Tang, J., Li, J., Zhu, X., Yuan, Y. J., Chen, D., Yuan, L., Gu, Z.-Y., Zhang, X., Qi, L., Gong, Z., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8710 · Cited by 54 · see citing works
Anti-MUC1 Nanobody Can Redirect T-Body Cytotoxic Effector Function
Aghaee‐Bakhtiari, S. H., Rahbarizadeh, F., Hasannia, S., Ahmadvand, D., Sofla, F. J. I., & Rasaee, M. J. (2009) · Hybridoma · doi:10.1089/hyb.2008.0079 · Cited by 53 · see citing works
Neutralizing Nanobodies Targeting Diverse Chemokines Effectively Inhibit Chemokine Function
Blanchetot, C., Verzijl, D., Mujić-Delić, A., Bosch, L., Rem, L., Leurs, R., Verrips, C. T., Saunders, M. J., de Haard, H., & Smit, M. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.467969 · Cited by 52 · see citing works
Bannas, P., Well, L., Lenz, A., Rissiek, B., Haag, F., Schmid, J., Hochgräfe, K., Trepel, M., Adam, G., Ittrich, H., et al. (2014) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1548 · Cited by 46 · see citing works
Anti‐c‐ MET Nanobody® – a new potential drug in multiple myeloma treatment
Slørdahl, T. S., Denayer, T., Moen, S. H., Standal, T., Børset, M., Ververken, C., & Rø, T. B. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12185 · Cited by 46 · see citing works
Khaleghi, S., Rahbarizadeh, F., Ahmadvand, D., Rasaee, M. J., & Pognonec, P. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1037-6 · Cited by 45 · see citing works
van Lith, S. A. M., van Duijnhoven, S. M. J., Navis, A. C., Leenders, W. P. J., Dolk, E., Wennink, J. W. H., van Nostrum, C. F., & van Hest, J. C. M. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00638 · Cited by 44 · see citing works
Zhu, Y., Bassoff, N., Reinshagen, C., Bhere, D., Nowicki, M. O., Lawler, S. E., Roux, J., & Shah, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-02483-9 · Cited by 44 · see citing works
Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody
Omidfar, K., Zanjani, F. S. A., Hagh, A. G., Azizi, M. D., Rasouli, S. J., & Kashanian, S. (2013) · Molecular Biology Reports · doi:10.1007/s11033-013-2790-1 · Cited by 43 · see citing works
Altıntaş, I., Kok, R. J., & Schiffelers, R. M. (2011) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2011.10.015 · Cited by 42 · see citing works
A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment
Farajpour, Z., Rahbarizadeh, F., Kazemi, B., & Ahmadvand, D. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.02.069 · Cited by 42 · see citing works
Nanobody-based chimeric receptor gene integration in Jurkat cells mediated by PhiC31 integrase
Sofla, F. J. I., Rahbarizadeh, F., Ahmadvand, D., & Rasaee, M. J. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.08.015 · Cited by 40 · see citing works
Even-Desrumeaux, K., Fourquet, P., Secq, V., Baty, D., & Chames, P. (2012) · Molecular BioSystems · doi:10.1039/c2mb25063b · Cited by 39 · see citing works
Araste, F., Ebrahimizadeh, W., Rasooli, I., Rajabibazl, M., & Gargari, S. L. M. (2013) · Biotechnology Letters · doi:10.1007/s10529-013-1340-1 · Cited by 38 · see citing works
Lehmann, A., Wixted, J. H. F., Shapovalov, M. V., Röder, H., Dunbrack, R. L., & Robinson, M. K. (2015) · mAbs · doi:10.1080/19420862.2015.1088618 · Cited by 34 · see citing works
AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model
Verhelle, A., Nair, N., Everaert, I., Overbeke, W. V., Supply, L., Zwaenepoel, O., Peleman, C., Dorpe, J. V., Lahoutte, T., Devoogdt, N., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx056 · Cited by 32 · see citing works
Drabek, D., Janssens, R., de Boer, E., Rademaker, R., Kloess, J., Skehel, J. J., & Grosveld, F. G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00619 · Cited by 31 · see citing works
Construction and expression of an anti-VEGFR2 Nanobody-Fc fusionbody in NS0 host cell
Qasemi, M., Behdani, M., Shokrgozar, M. A., Kazemiha, V. M., Mohseni-Kuchesfahani, H., & Habibi‐Anbouhi, M. (2016) · Protein Expression and Purification · doi:10.1016/j.pep.2016.03.004 · Cited by 30 · see citing works
Bannas, P., Lenz, A., Kunick, V., Fumey, W., Rissiek, B., Schmid, J., Haag, F., Leingärtner, A., Trepel, M., Adam, G., et al. (2015) · Journal of Visualized Experiments · doi:10.3791/52462 · Cited by 25 · see citing works
The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells
Mo, Z., Du, P., Wang, G., & Wang, Y. (2017) · Journal of Cancer · doi:10.7150/jca.18681 · Cited by 24 · see citing works
Selection and characterization of camelid nanobodies towards urokinase-type plasminogen activator
Kaczmarek, J. Z., & Skottrup, P. D. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.02.011 · Cited by 14 · see citing works
Design and screening of a chimeric survivin-specific nanobody and its anticancer activities in vitro
Zhang, N., Guo, H., Zheng, W., Wang, T., & Ma, X. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000394 · Cited by 14 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749 · see citing works
Extracellular ATP and P2 purinergic signalling in the tumour microenvironment
Virgilio, F. D., Sarti, A. C., Falzoni, S., Marchi, E. D., & Adinolfi, E. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0037-0 · Cited by 730 · see citing works
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 646 · see citing works
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Gurbatri, C. R., Lia, I., Vincent, R., Coker, C., Castro, S., Treuting, P. M., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0876 · Cited by 647 · see citing works
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 528 · see citing works
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Xiao, L., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 461 · see citing works
An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction
Hanke, L., Vidakovics, L. P., Sheward, D. J., Das, H., Schulte, T. P., Moliner-Morro, A., Corcoran, M., Achour, A., Hedestam, G. B. K., Hällberg, B. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18174-5 · Cited by 327 · see citing works
Bispecific Antibodies: From Research to Clinical Application
Ma, J., Mo, Y., Tang, M., Shen, J., Qi, Y., Zhao, W., Huang, Y., Xu, Y., & Qian, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626616 · Cited by 310 · see citing works
Considerations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 305 · see citing works
Di Virgilio, F., Schmalzing, G., & Markwardt, F. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.01.005 · Cited by 279 · see citing works
Computational approaches to therapeutic antibody design: established methods and emerging trends
Norman, R. A., Ambrosetti, F., Bonvin, A. M. J. J., Colwell, L. J., Kelm, S., Kumar, S., & Krawczyk, K. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz095 · Cited by 219 · see citing works
“The accumulated methodology of computational antibody protocols could potentially be applied to novel antibody formats with intrinsically better biophysical properties, such as nanobodies [27].”
BackgroundA comprehensive comparison between camelid nanobodies and single chain variable fragments
Asaadi, Y., Jouneghani, F. F., Janani, S., & Rahbarizadeh, F. (2021) · Biomarker Research · doi:10.1186/s40364-021-00332-6 · Cited by 209 · see citing works
Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics
Li, H., Saw, P. E., & Song, E. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0417-8 · Cited by 202 · see citing works
Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems
Shi, M., & McHugh, K. J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114904 · Cited by 194 · see citing works
Nanobody: a promising toolkit for molecular imaging and disease therapy
Bao, G., Tang, M., Zhao, J., & Zhu, X. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00750-5 · Cited by 185 · see citing works
Nanobody-based CAR-T cells for cancer immunotherapy
Kozani, P. S., Naseri, A., Mirarefin, S. M. J., Salem, F., Nikbakht, M., Bakhshi, S. E., & Kozani, P. S. (2022) · Biomarker Research · doi:10.1186/s40364-022-00371-7 · Cited by 185 · see citing works
Bispecific antibodies: advancing precision oncology
Herrera, M., Pretelli, G., Desai, J., Garralda, E., Siu, L. L., Steiner, T. M., & Au, L. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.07.002 · Cited by 187 · see citing works
Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
Davda, J. P., Declerck, P. J., Hu‐Lieskovan, S., Hickling, T. P., Jacobs, I. A., Chou, J., Salek‐Ardakani, S., & Kraynov, E. A. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0586-0 · Cited by 181 · see citing works
Nanobody—A versatile tool for cancer diagnosis and therapeutics
Liu, M., Li, L., Jin, D., & Liu, Y. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1697 · Cited by 158 · see citing works
Electrochemical Sensors to Detect Bacterial Foodborne Pathogens
Castle, L. M., Schuh, D. A., Reynolds, E. E., & Furst, A. L. (2021) · ACS Sensors · doi:10.1021/acssensors.1c00481 · Cited by 158 · see citing works
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 156 · see citing works
Theranostics in immuno-oncology using nanobody derivatives
Lecocq, Q., Vlaeminck, Y. D., Hanssens, H., D’Huyvetter, M., Raes, G., Goyvaerts, C., Keyaerts, M., Devoogdt, N., & Breckpot, K. (2019) · Theranostics · doi:10.7150/thno.34941 · Cited by 145 · see citing works
Optophysiology: Illuminating cell physiology with optogenetics
Tan, P., He, L., Huang, Y., & Zhou, Y. (2022) · Physiological Reviews · doi:10.1152/physrev.00021.2021 · Cited by 136 · see citing works
Strohl, W. R., & Naso, M. F. (2019) · Antibodies · doi:10.3390/antib8030041 · Cited by 136 · see citing works
Nessler, I., Khera, E., Vance, S., Kopp, A., Qiu, Q., Keating, T. A., Abu-Yousif, A. O., Sandal, T., Legg, J., Thompson, L., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2295 · Cited by 128 · see citing works
Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy
Sun, S., Ding, Z., Yang, X., Zhao, X., Zhao, M., Gao, L., Chen, Q., Xie, S., Liu, A., Yin, S., et al. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s297631 · Cited by 131 · see citing works
Antibody display technologies: selecting the cream of the crop
Valldorf, B., Hinz, S. C., Russo, G., Pekar, L., Mohr, L., Klemm, J., Doerner, A., Krah, S., Hust, M., & Zielonka, S. (2021) · Biological Chemistry · doi:10.1515/hsz-2020-0377 · Cited by 130 · see citing works
CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging
Ulaner, G. A., Sobol, N. B., O’Donoghue, J. A., Kirov, A. S., Riedl, C. C., Min, R. K., Smith, E., Carter, L. M., Lyashchenko, S. K., Lewis, J. S., et al. (2020) · Radiology · doi:10.1148/radiol.2020192621 · Cited by 128 · see citing works
NLRP3 inflammasome signalling in Alzheimer's disease
McManus, R. M., & Latz, E. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109941 · Cited by 125 · see citing works
Verhaar, E. R., Woodham, A. W., & Ploegh, H. L. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101425 · Cited by 115 · see citing works
Targeted Nanobody-Based Molecular Tracers for Nuclear Imaging and Image-Guided Surgery
Debie, P., Devoogdt, N., & Hernot, S. (2019) · Antibodies · doi:10.3390/antib8010012 · Cited by 112 · see citing works
The Application of Nanobody in CAR-T Therapy
Bao, C., Gao, Q., Li, L., Han, L., Zhang, B., Ding, Y., Song, Z., Zhang, R., Zhang, J., & Wu, X.-H. (2021) · Biomolecules · doi:10.3390/biom11020238 · Cited by 111 · see citing works
Ma, L., Zhu, M., Gai, J., Li, G., Chang, Q. H., Peng, Q., Cao, L., Chen, W., Zhang, S., & Wan, Y. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-0571-2 · Cited by 110 · see citing works
Soluble ligands as drug targets
Attwood, M. M., Jonsson, J., Rask‐Andersen, M., & Schiöth, H. B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0078-4 · Cited by 110 · see citing works
Zhao, G., He, L., Sun, S., Qiu, H., Tai, W., Chen, J., Li, J., Chen, Y., Guo, Y., Wang, Y., et al. (2018) · Journal of Virology · doi:10.1128/jvi.00837-18 · Cited by 101 · see citing works
Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
Versteven, M., den Bergh, J. M. J. V., Marcq, E., Smits, E., Tendeloo, V. F. V., Hobo, W. A., & Lion, E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00394 · Cited by 97 · see citing works
Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy
Babamohamadi, M., Mohammadi, N., Faryadi, E., Haddadi, M., Merati, A., Ghobadinezhad, F., Amirian, R., Izadi, Z., & Hadjati, J. (2024) · Cell Death and Disease · doi:10.1038/s41419-023-06391-x · Cited by 101 · see citing works
The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy
Kabir, E. R., Moreino, S. S., & Siam, M. K. S. (2019) · Biomolecules · doi:10.3390/biom9090410 · Cited by 92 · see citing works
Lu, Q., Zhang, Z., Li, H., Zhong, K., Zhao, Q., Wang, Z., Wu, Z., Yang, D., Sun, S., Yang, N., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00768-w · Cited by 89 · see citing works
Ivermectin induces cell cycle arrest and apoptosis of HeLa cells via mitochondrial pathway
Zhang, P., Zhang, Y., Liu, K., Liu, B., Xu, W., Gao, J., Ding, L., & Tao, L. (2018) · Cell Proliferation · doi:10.1111/cpr.12543 · Cited by 89 · see citing works
Nanotechnology-Based Strategies to Overcome Current Barriers in Gene Delivery
Mirón-Barroso, S., Domènech, E. B., & Trigueros, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168537 · Cited by 91 · see citing works
Directing evolution of novel ligands by mRNA display
Kamalinia, G., Grindel, B. J., Takahashi, T. T., Millward, S. W., & Roberts, R. W. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00160d · Cited by 88 · see citing works
Nanobody-Targeted Photodynamic Therapy Selectively Kills Viral GPCR-Expressing Glioblastoma Cells
Groof, T. W. M. D., Mashayekhi, V., Fan, T. S., Bergkamp, N. D., Toraño, J. S., van Senten, J. R., Heukers, R., Smit, M. J., & Oliveira, S. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00360 · Cited by 82 · see citing works
The Many Applications of Engineered Bacteriophages—An Overview
Gibb, B., Hyman, P., & Schneider, C. B. (2021) · Pharmaceuticals · doi:10.3390/ph14070634 · Cited by 84 · see citing works
Gao, W., Wang, Y., Xiong, Y., Sun, L., Wang, L., Wang, K., Lu, H. Y., Bao, A., Turvey, S. E., Li, Q., et al. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.12.046 · Cited by 82 · see citing works
Next generation radiotheranostics promoting precision medicine
Pomykala, K. L., Hadaschik, B. A., Sartor, O. A., Gillessen, S., Sweeney, C. J., Maughan, T., Hofman, M. S., & Herrmann, K. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.03.001 · Cited by 82 · see citing works
Nanobodies: The “Magic Bullets” in therapeutics, drug delivery and diagnostics
Mir, M. A., Mehraj, U., Sheikh, B. A., & Hamdani, S. S. (2019) · Human Antibodies · doi:10.3233/hab-190390 · Cited by 80 · see citing works
Identification and in vivo characterization of a brain-penetrating nanobody
Wouters, Y., Jaspers, T., Strooper, B. D., & Dewilde, M. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00226-z · Cited by 80 · see citing works
Becker, J., Fakhiri, J., & Grimm, D. (2022) · Pathogens · doi:10.3390/pathogens11070756 · Cited by 80 · see citing works
Nanobodies: Robust miniprotein binders in biomedicine
Kim, J. Y. J., Sang, Z., Xiang, Y., Shen, Z., & Shi, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114726 · Cited by 78 · see citing works
Targeted Repolarization of Tumor‐Associated Macrophages via Imidazoquinoline‐Linked Nanobodies
Bolli, E., Scherger, M., Arnouk, S. M., Antunes, A. R. P., Straßburger, D., Urschbach, M., Stickdorn, J., Vlaminck, K. D., Movahedi, K., Räder, H. J., et al. (2021) · Advanced Science · doi:10.1002/advs.202004574 · Cited by 77 · see citing works
Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape
Mast, F. D., Fridy, P. C., Ketaren, N. E., Wang, J., Jacobs, E. Y., Olivier, J. P., Sanyal, T., Molloy, K. R., Schmidt, F., Rutkowska, M., et al. (2021) · eLife · doi:10.7554/elife.73027 · Cited by 67 · see citing works
Nanobodies as efficient drug-carriers: Progress and trends in chemotherapy
Panikar, S. S., Banu, N., Haramati, J., del Toro‐Arreola, S., Leal, A. R., & Salas, P. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.004 · Cited by 74 · see citing works
Research progress and applications of nanobody in human infectious diseases
Mei, Y., Chen, Y., Sivaccumar, J. P., An, Z., Xia, N., & Luo, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.963978 · Cited by 70 · see citing works
Taheri, F. H., Hassani, M., Sharifzadeh, Z., Behdani, M., Arashkia, A., & Abolhassani, M. (2019) · IUBMB Life · doi:10.1002/iub.2019 · Cited by 69 · see citing works
Anti-LRP5/6 VHHs promote differentiation of Wnt-hypersensitive intestinal stem cells
Fenderico, N., van Scherpenzeel, R. C., Goldflam, M., Proverbio, D., Jordens, I., Kralj, T., Stryeck, S., Bass, T. Z., Hermans, G., Ullman, C. G., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08172-z · Cited by 64 · see citing works
Advances in antibody engineering for rheumatic diseases
Schmid, A. S., & Neri, D. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0188-8 · Cited by 68 · see citing works
Psoriasis: Recent progress in molecular‐targeted therapies
Honma, M., & Hayashi, K. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15727 · Cited by 68 · see citing works
CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities
Akhoundi, M., Mohammadi, M., Sahraei, S. S., Sheykhhasan, M., & Hosseini, N. F. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00593-1 · Cited by 65 · see citing works
Hambach, J., Riecken, K., Cichutek, S., Schütze, K., Albrecht, B., Petry, K., Röckendorf, J. L., Baum, N., Kröger, N. M., Hansen, T., et al. (2020) · Cells · doi:10.3390/cells9020321 · Cited by 64 · see citing works
A single-domain antibody inhibits SFTSV and mitigates virus-induced pathogenesis in vivo
Wu, X., Li, Y., Huang, B., Ma, X., Zhu, L., Zheng, N., Xu, S., Nawaz, W., Xu, C., & Wu, Z. (2020) · JCI Insight · doi:10.1172/jci.insight.136855 · Cited by 64 · see citing works
Therapeutic applications of nanobiotechnology
Dutt, Y., Pandey, R. P., Dutt, M., Gupta, A. A., Vibhuti, A., Vidić, J., Raj, V. S., Chang, C.-M., & Priyadarshini, A. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01909-z · Cited by 68 · see citing works
Khalique, H., Baugh, R. T., Dyer, A., Scott, E. M., Frost, S., Larkin, S. J., Lei-Rossmann, J., & Seymour, L. W. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001292 · Cited by 62 · see citing works
Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer
Tapia-Galisteo, A., Sánchez-Rodríguez, I., Aguilar-Sopeña, Ó., Harwood, S. L., Narbona, J., Ferreras-Gutiérrez, M., Navarro, R., Martín-García, L., Corbacho, C., Compte, M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2034355 · Cited by 62 · see citing works
Nanobodies: New avenues for imaging, stabilizing and modulating GPCRs
Groof, T. W. M. D., Bobkov, V., Heukers, R., & Smit, M. J. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.01.021 · Cited by 62 · see citing works
de Weerdt, I., Lameris, R., Ruben, J. M., de Boer, R., Kloosterman, J., King, L. A., Levin, M., Parren, P. W. H. I., de Gruijl, T. D., Kater, A. P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4576 · Cited by 62 · see citing works
Li, Y., & Champion, J. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114462 · Cited by 62 · see citing works
Siepe, D. H., Picton, L. K., & García, K. C. (2023) · ACS Synthetic Biology · doi:10.1021/acssynbio.2c00587 · Cited by 61 · see citing works
Perspectives on metals-based radioimmunotherapy (RIT): moving forward
White, J. M., Escorcia, F. E., & Viola, N. T. (2021) · Theranostics · doi:10.7150/thno.57177 · Cited by 60 · see citing works
Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer
Ma, H., Das, J. P., Prendergast, C. M., de Jong, D., Braumuller, B., Paily, J., Huang, S., Liou, C., Giarratana, A. O., Hosseini, M., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45110566 · Cited by 61 · see citing works
Single domain antibody: Development and application in biotechnology and biopharma
Yu, T., Zheng, F., He, W., Muyldermans, S., & Wen, Y. (2024) · Immunological Reviews · doi:10.1111/imr.13381 · Cited by 61 · see citing works
Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins
Tan, H., Su, W., Zhang, W., Wang, P., Sattler, M., & Zou, P. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190206105232 · Cited by 59 · see citing works
Nanobodies detecting and modulating GPCRs outside in and inside out
Heukers, R., Groof, T. W. M. D., & Smit, M. J. (2019) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2019.01.003 · Cited by 59 · see citing works
Nanobodies in cell-mediated immunotherapy: On the road to fight cancer
Maali, A., Gholizadeh, M., Feghhi-Najafabadi, S., Noei, A., Seyed-Motahari, S. S., Mansoori, S., & Sharifzadeh, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1012841 · Cited by 62 · see citing works
O-acetylated Gangliosides as Targets for Cancer Immunotherapy
Cavdarli, S., Delannoy, P., & Groux‐Degroote, S. (2020) · Cells · doi:10.3390/cells9030741 · Cited by 58 · see citing works
Easily Established and Multifunctional Synthetic Nanobody Libraries as Research Tools
Liu, B., & Yang, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031482 · Cited by 57 · see citing works
Treating Parkinson’s Disease with Antibodies: Previous Studies and Future Directions
Castonguay, A.-M., Gravel, C., & Lévesque, M. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202221 · Cited by 55 · see citing works
Mahmud, N., Anik, M. I., Hossain, M. K., Khan, M. I., Uddin, S., Ashrafuzzaman, M., & Rahaman, M. M. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00123 · Cited by 53 · see citing works
Nanobodies for Medical Imaging: About Ready for Prime Time?
Berland, L., Kim, L., Abousaway, O., Mines, A., Mishra, S., Clark, L. M., Hofman, P. M., & Rashidian, M. (2021) · Biomolecules · doi:10.3390/biom11050637 · Cited by 52 · see citing works
Antibody design using deep learning: from sequence and structure design to affinity maturation
Joubbi, S., Micheli, A., Milazzo, P., Maccari, G., Ciano, G., Cardamone, D., & Medini, D. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae307 · Cited by 54 · see citing works
Ye, J., Guo, J., Li, T., Tian, J., Yu, M., Wang, X., Majeed, U., Song, W., Xiao, J., Luo, Y., et al. (2022) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12908 · Cited by 51 · see citing works
Kolesnik, V. V., Nurtdinov, R. F., Oloruntimehin, E. S., Karabelsky, A. V., & Malogolovkin, A. S. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1607 · Cited by 51 · see citing works
Schütze, K., Petry, K., Hambach, J., Schuster, N., Fumey, W., Schriewer, L., Röckendorf, J. L., Menzel, S., Albrecht, B., Haag, F., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02553 · Cited by 50 · see citing works
Current Trends in Cancer Immunotherapy
Filin, I. Y., Solovyeva, V. V., Kitaeva, K. V., Rutland, C. S., & Rizvanov, A. A. (2020) · Biomedicines · doi:10.3390/biomedicines8120621 · Cited by 50 · see citing works
Photobodies: Light‐Activatable Single‐Domain Antibody Fragments
Jedlitzke, B., Yilmaz, Z., Dörner, W., & Mootz, H. D. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201912286 · Cited by 49 · see citing works
Macpherson, A. M., Barry, S. C., Ricciardelli, C., & Oehler, M. K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092967 · Cited by 48 · see citing works
Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
You, G., Won, J., Lee, Y., Moon, D., Park, Y., Lee, S. H., & Lee, S. (2021) · Vaccines · doi:10.3390/vaccines9070724 · Cited by 48 · see citing works
Prospects for the computational humanization of antibodies and nanobodies
Gordon, G. L., Raybould, M. I. J., Wong, A., & Deane, C. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1399438 · Cited by 47 · see citing works
Aptamer-based assembly systems for SARS-CoV-2 detection and therapeutics
Dong, Y., Wang, J., Chen, L., Chen, H., Dang, S., & Li, F. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00774j · Cited by 46 · see citing works
Developability considerations for bispecific and multispecific antibodies
Amash, A., Volkers, G., Farber, P. J., Griffin, D., Davison, K. S., Goodman, A., Tonikian, R., Yamniuk, A. P., Barnhart, B. C., & Jacobs, T. M. (2024) · mAbs · doi:10.1080/19420862.2024.2394229 · Cited by 50 · see citing works
Novel biologics targeting the P2X7 ion channel.
Koch-Nolte, F., Eichhoff, A., Pinto-Espinoza, C., Schwarz, N., Schäfer, T., Menzel, S., Haag, F., Demeules, M., Gondé, H., & Adriouch, S. (2019) · Current opinion in pharmacology (Print) · doi:10.1016/j.coph.2019.03.001 · Cited by 44 · see citing works
Bioactive cell penetrating peptides and proteins in cancer: a bright future ahead
Jauset, T., & Beaulieu, M.-È. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.03.014 · Cited by 46 · see citing works
AAV‐mediated delivery of an anti‐BACE1 VHH alleviates pathology in an Alzheimer's disease model
Marino, M., Zhou, L., Rincón, M. Y., Callaerts‐Vegh, Z., Verhaert, J., Wahis, J., Creemers, E., Yshii, L., Wierda, K. D. B., Saito, T., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.201809824 · Cited by 45 · see citing works
Schiffelers, L. D. J., Tesfamariam, Y. M., Jenster, L., Diehl, S., Binder, S. C., Normann, S., Mayr, J., Pritzl, S., Hagelauer, E., Kopp, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52110-1 · Cited by 45 · see citing works
Mendoza, M. N., Jian, M., King, M. T., & Brooks, C. L. (2020) · Protein Science · doi:10.1002/pro.3831 · Cited by 45 · see citing works
Nanobodies as novel therapeutic agents in envenomation
Alirahimi, E., Kazemi‐Lomedasht, F., Shahbazzadeh, D., Habibi‐Anbouhi, M., Hosseininejad-Chafi, M., Sotoudeh, N., Ghaderi, H., Muyldermans, S., & Behdani, M. (2018) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2018.08.019 · Cited by 44 · see citing works
Modeling and affinity maturation of an anti-CD20 nanobody: a comprehensive in-silico investigation
Poustforoosh, A., Faramarz, S., Negahdaripour, M., & Hashemipour, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-27926-4 · Cited by 43 · see citing works
Wang, L., Zhang, L., Huang, B., Li, K., Hou, G., Zhao, Q., Wu, C., Nan, Y., Du, T., Mu, Y., et al. (2018) · Journal of Virology · doi:10.1128/jvi.01888-18 · Cited by 43 · see citing works
A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade
Ma, L., Gai, J., Qiao, P., Li, Y., Li, X., Zhu, M., Li, G., & Wan, Y. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.07.072 · Cited by 43 · see citing works
50 Years of structural immunology
Wilson, I. A., & Stanfield, R. L. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100745 · Cited by 43 · see citing works
- Authors
- Bannas, P., Hambach, J., & Koch-Nolte, F.
- Affiliations
- University Medical Center Hamburg-Eppendorf (DE)
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2017-11-22
- Volume
- 8
- Pages
- 1603-1603
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC5702627
- OpenAlex
- W2769445535
- Cited by
- 572
- References
- 134
- Citations by year
- 2026: 51 · 2025: 68 · 2024: 93 · 2023: 62 · 2022: 70 · 2021: 85 · 2020: 68 · 2019: 48 · 2018: 27
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Wilhelm Sander-Stiftung (2012.113.2)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Keywords
- nanobodies, VHH, camelid antibodies, antibody engineering, tumor targeting, antibody aggregation, bispecific T-cell engagers, antibody-drug conjugates, radionuclide conjugation, photosensitizer conjugation, nanoparticle conjugation, cancer immunotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
